Efficacy and short-term safety of intravenous omadacycline as second-line therapy for macrolide- unresponsive Mycoplasma pneumoniae pneumonia in children: a retrospective cohort study.

On multivariate linear regression, continued macrolide therapy (B = 13.43 h, 95% CI: 2.02-24.84, P = 0.022), positive 23S rRNA mutation status (B = 20.85 h, 95% CI: 10.94-30.77, P<0.001), and systemic corticosteroid use (B = 21.21 h, 95% CI: 10.79-31.62, P<0.001) were independently associated with prolonged TTD.

No significant difference was observed in radiological improvement (P = 0.668).

At 3-month follow-up, no clinically significant changes were observed in hematological indices, hepatic or renal function, or cardiac enzyme profiles, and dental examination revealed no discoloration or enamel hypoplasia in any patient.